Bevacizumab. Progress in cancer therapy by antiangiogenesis;Bevacizumab. Fortschritte in der krebstherapie mit antiangiogenese

Medizinische Monatsschrift fur Pharmazeuten

Volumn 29, Issue 7, 2006, Pages 249-254

  Krämer, Irene ^a,b,d   Lipp, Hans Peter ^a,c,e  

^a Klinikums der Johannes Gutenberg Universität Mainz ^*

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Universität Mainz ^*  (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ANTIANGIOGENIC ACTIVITY; BLEEDING; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; COST; DRUG METABOLISM; HUMAN; HYPERTENSION; PROTEINURIA; REVIEW; THROMBOEMBOLISM; WOUND HEALING;

EID: 33746847683     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Avastin (bevacizumab) package insert. South San Francisco, CA: Genentech, Jan. 2005.
2. Fayette J, Soria JC, Armand JP. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005;41:1109-16.
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev 2004;3:391-400.
4. Folkman J. Clinical implications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
5. Gaudreault J. Pharmacokinetics of bevacizumab in colorectal cancer. Clin Pharmacol Ther 2001;69(Suppl 2):P25.
6. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab in combination with Folfox4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200.www.asco.org/ac/1,1003_12-002636-00_18-0036-00_19-0010294,00. asp (accessed 2005 Feb 14).
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
8. Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004;61:21-6.
9. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542.
10. Kolesar JM. Bevacizumab: Improved survival at what cost? Am J Health Syst Pharm 2005;62:1017.
11. Lipp HP, Krämer I. ADKA-Statement: Aseptische Herstellung applikationsfertiger Zubereitungen von monoklonalen Antikörpern für die Antitumortherapie. Krankenhauspharmazie 2004;25:91-3.
12. Marmé D. Anti-Angiogenese - Ein neues therapeutisches Prinzip in der Krebsbehandlung; Hemmung der Tumor-Angiogenese. InFo Onkologie Beilage_CME Spezial 2005;1:3-15.
13. Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004;350:2406-8.
14. Miller KD, Chap LI, Holmes F, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23: 792-9.
15. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 2005;62:1021-32.
16. Nissen NN, Polverini PJ, Koch AE, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998;152:1445-52.
17. Ostendorf T, Kunter U, Eitner F, et al. VEGF165 mediates glomerular endothelial repair. J Clin Invest 1999;104:913-23.
18. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002;105:43-7.
19. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non small cell lung cancer. Proceedings of ASCO, 2005: LBA4.
20. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 2005;23:2574-6.
21. Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 2005;17:578-83.
22. Zondor SD, Medina PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004;38:1258-64.